Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MHC Class II Transactivator Is an In Vivo Regulator of Osteoclast Differentiation and Bone Homeostasis Co-opted From Adaptive Immunity

3 Sept 2013

Abstract excerpt

The molecular networks controlling bone homeostasis are not fully understood. The common evolution of bone and adaptive immunity encourages the investigation of shared regulatory circuits. MHC Class II Transactivator (CIITA) is a master transcriptional co-activator believed to be exclusively dedicated for antigen presentation. CIITA is expressed in osteoclast precursors, and its expression is accentuated in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Metabolism and Diseases
Share to Chemokine receptors and signaling
Share to Cytokine Signaling Pathways and Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24038328
DOI: 10.1002/jbmr.2090

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MHC Class II Transactivator Is an In Vivo Regulator of Osteoclast Differentiation and Bone Homeostasis Co-opted From Adaptive ImmunityPMID 24038328Read ↗

Immunology and boneSemantic proximity Read ↗

Monocyte Subsets with High Osteoclastogenic Potential and Their Epigenetic Regulation Orchestrated by IRF8Semantic proximity Read ↗

C/EBPα regulates osteoclast lineage commitment.Semantic proximity Read ↗

Id1 represses osteoclast-dependent transcription and affects bone formation and hematopoiesis.Semantic proximity Read ↗

MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCARSemantic proximity Read ↗

Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of Cx3cr1.Semantic proximity Read ↗

Therapeutic interleukin-2 rewires skeletal-immune circuits to reverse postmenopausal bone lossSemantic proximity Read ↗

Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis.Semantic proximity Read ↗

Autoamplification of NFATc1 expression determines its essential role in bone homeostasisSemantic proximity Read ↗

Sustained Notch2 signaling in osteoblasts, but not in osteoclasts, is linked to osteopenia in a mouse model of Hajdu-Cheney syndrome.Semantic proximity Read ↗

The molecular understanding of osteoclast differentiationSemantic proximity Read ↗

Blimp1-mediated repression of negative regulators is required for osteoclast differentiationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.